-
| Industry | Biotechnology |
|---|---|
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US05338F3064 |
| Sector | Healthcare |
| Market Cap | 54M |
|---|---|
| PE Ratio | None |
| Target Price | 31.3333 |
| Beta | 0.88 |
| Dividend Yield | None |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AVTX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025